(Press-News.org) April 23, 2015, Vienna, Austria: As many as half of people infected with viral hepatitis have suffered discrimination and one-quarter admit that family members have avoided physical contact with them after finding out they had the infection. A shocking patient survey presented at The International Liver CongressTM 2015 has shown the devastating impact the infection has on their daily lives.
Research conducted with the Ministry of Health in Brazil questioned 1,217 people infected with hepatitis B or C in Europe and America using an online survey tool. The aim of the research was to find out, from those infected, when and with what intensity stigma and discrimination affect their quality of life.
The survey revealed that nearly half (49.6%) of those infected have suffered some kind of discrimination. Of the 94.1% who told their family they had the infection, a quarter (24.6%) said that relatives started to avoid physical contact. Furthermore, of the 73.7% who told friends about their condition, nearly half (46.9%) said they suffered discrimination and 23.8% said they were no longer invited to social events.
"Few studies have evaluated the circumstances and the degree to which stigma and discrimination are present for those living with viral hepatitis. This is one of the first studies that listens to the voice of the patient in order to find out from them the context and intensity of stigma and discrimination that they experience and how it affects their quality of life," said Carlos Varaldo, president of Grupo Otimismo 'Support Group for People Who Live with Hepatitis'.
Of the 57.4% of those infected with viral hepatitis who told their partner about their condition, 33.3% said it affected their relationship and nearly half (42.7%) said it had an impact on their sex life.
Stigma and discrimination was also found to heavily impact the workplace. Of the 46.1% who told work colleagues, 10.1% lost their jobs. Self-image was affected in 55.8% of the cases and 41.4% said they felt ashamed of their condition.
The survey indicates that 70% of health professionals looked after sufferers properly; however, 24.6% of those health professionals have maintained a certain distance from the patient and 6.9% denied care to people infected with hepatitis, the survey revealed.
"This shocking survey highlights the true toll viral hepatitis can have on people's lives. Not only are these people dealing with the illness, it is very evident that viral hepatitis infection still has a major stigma attached to it across all areas of people's lives, including their family life and even the workplace," said Marcelo C. M. Naveira - Viral Hepatitis Coordination, Secretariat for Disease Surveillance Ministry of Health of Brazil.
"The stigma and discrimination faced by people living with hepatitis is all too often based on misunderstandings about the virus and its transmission. Not only is this damaging to people diagnosed with the disease, but it may also discourage others from getting tested and accessing treatment and support. There is a pressing need to educate the general public about hepatitis to erode this stigma and break down barriers to timely testing, treatment and care for those who need it," said Professor Markus Peck, Secretary General, European Association for the Study of the Liver.
About The International Liver Congress™
This annual congress is the biggest event in the EASL calendar, attracting scientific and medical experts from around the world to learn about the latest in liver research. Specialists share research studies and findings, and discuss the hottest topics related to liver disease. This year, the congress is expected to attract approximately 10,000 delegates from all corners of the globe. 2015 is a very special year for EASL and the hepatology community as they will celebrate the 50th annual meeting. The International Liver Congress™ takes place from April 22-26, 2015, Vienna, Austria.
About EASL (http://www.easl.eu)
Since EASL's foundation in 1966, this not-for-profit organisation has grown to over 4,000 members from more than 100 countries around the world. EASL is the leading liver association in Europe, it attracts the foremost hepatology experts and has an impressive track record in promoting research in liver disease, supporting wider education and promoting changes in European liver policy.
Contact
For more information, please contact the ILC Press Office at:
* ilc.press@easloffice.eu or
* +44 (0)20 3580 5444
INFORMATION:
April 23, 2015, Vienna, Austria: Data presented today at The International Liver Congress™ 2015 demonstrates that remogliflozin etabonate, an investigational drug in type 2 diabetes, is a potential treatment option for the management of patients with non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).
In clinical studies, remogliflozin etabonate was shown to significantly improve insulin sensitivity and beta cell function, as well as reduce body weight and levels of alanine aminotransferase (ALT). In pre-clinical studies, remogliflozin ...
April 23, 2015, Vienna, Austria: New data from an ongoing Phase III trial revealed today at The International Liver CongressTM 2015 show that the use of hepatitis C immune globulin (HCIG, Civacir®) can effectively prevent hepatitis C virus (HCV) recurrence in patients following a liver transplant (LT). The data demonstrate that intravenous Civacir given both peri- and post-LT prevents HCV-reinfection in patients who also received antiviral therapy (AVT) before their transplant operation.
Civacir is a hepatitis C immune globulin (HCIG) produced from pooled plasma ...
April 23, 2015, Vienna, Austria: Results from a double-blind, placebo-controlled study of silymarin, which is derived from the milk thistle plant, have shown that this herbal remedy may be a useful treatment option for non-alcoholic steatohepatitis (NASH).
An interim analysis of the study, revealed today at The International Liver Congress™ 2015, shows a significantly higher percentage of patients experienced NASH resolution and improvement in fibrosis after 48 weeks of treatment with silymarin compared to placebo.
NASH occurs when the liver becomes inflamed ...
April 23, 2015, Vienna, Austria: Many countries in the World Health Organization (WHO) European Region are facing limitations in conducting chronic viral hepatitis disease surveillance, assessing the burden of disease and measuring the impact of interventions, according to results revealed today at The International Liver Congress™ 2015.
The study highlights that less than one-third (27%) of WHO European Member States have national strategies in place that contain a surveillance component. Furthermore, only 64% have a national surveillance system for chronic hepatitis ...
April 23, 2015, Vienna, Austria: A new study revealed today at The International Liver CongressTM 2015 shows that sofosbuvir (SOF)-based regimens are effective and well tolerated in hepatitis C and HIV co-infected, cirrhotic patients. Sustained virologic response at 4 weeks (SVR4) was observed in 98% of patients and in 95% at 12 weeks (SVR12).
The results are particularly encouraging as this patient group is considered difficult-to-treat and has a high mortality rate. The study included 142 patients of different hepatitis C virus (HCV) genotypes who were initiated onto ...
April 23, 2015, Vienna, Austria: Interim data presented today at The International Liver CongressTM 2015 from the HCV-TARGET study show that all-oral, direct-acting antiviral therapy for hepatitis C (HCV) is well tolerated and highly effective in patients with decompensated cirrhosis. Sustained virologic response (SVR) at 4 weeks was shown to be: sofosbuvir/ribavirin: 75%; sofosbuvir/simeprevir: 77%; sofosbuvir/simeprevir/ribavirin: 81%.
These results demonstrate that all-oral, direct-acting antiviral regimens are better tolerated and achieve higher rates of SVR in HCV ...
April 23, 2015, Vienna, Austria: Data revealed today at The International Liver Congress™ 2015 highlights the impact of delaying treatment for the hepatitis C virus (HCV). Researchers found that treatment delays have a serious detrimental effect on treatment efficacy, increasing the risk of morbidity and mortality among patients.
The study was conducted using retrospective patient data from the Veterans Administration in the USA to estimate the impact on risk of morbidity and death depending on whether treatment was initiated before or after a patient's FIB4 levels ...
April 23, 2015, Vienna, Austria: Results revealed today at The International Liver Congress™ 2015 demonstrate current treatment and prevention programmes need to be scaled up in order to make elimination of hepatitis B virus (HBV) possible.
The study conducted by Imperial College Scientists, highlights that if existing interventions, such as infant hepatitis B vaccination and treatment programmes, were scaled up, the number of new chronic HBV infections could be reduced by 90% and mortality levels could be reduced by 65% by 2030. Globally, this would mean 13 million ...
April 23, 2015, Vienna, Austria: A new device has demonstrated it has the potential to enhance the viability of donor livers for transplantation. Results revealed today at The International Liver Congress™ 2015 show that the transportable machine perfusion (MP) Airdrive® is able to effectively maintain the quality of livers derived from donation after circulatory death (DCD).
Many centers are reluctant to use DCD livers since they might jeopardize graft function post-transplantation. Contrary to 'classical' heart-beating donors (HBD), livers from DCDs undergo ...
April 23, 2015, Vienna, Austria: New data presented today at The International Liver CongressTM 2015 show that the intensity of weight loss induced by lifestyle changes is strongly linked with the grade of improvement of various histological features of NASH. Weight loss of more than 7% results in a positive impact on most histological parameters; however, to induce steatohepatitis resolution, and fibrosis and portal inflammation improvements, over 10% weight loss is needed.
The study was conducted in 293 patients with histologically proven NASH. Patients were treated ...
